All articles by Swagath Bandhakavi
Swagath Bandhakavi
GSK and Boston University team up for pulmonary fibrosis research
The partnership seeks to enhance the understanding of pulmonary fibrosis and discover new drug targets by utilising lung cells developed by CReM
OmniaBio opens new commercial manufacturing facility in Canada, bringing life-saving cell and gene therapies to patients
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients
Merck’s clesrovimab significantly cuts RSV hospitalisations in MK-1654-004 trial
The findings showed an over 84% reduction in RSV-related hospitalisations and more than 90% in hospitalisations linked to RSV-related lower respiratory infections during a five-month observation period
FDA approves Genentech’s Itovebi for advanced breast cancer with PIK3CA mutation
In the INAVO120 study, Itovebi reduced the risk of disease progression or death by 57% when combined with palbociclib and fulvestrant, compared to using palbociclib and fulvestrant alone
Sanofi in talks with CD&R for sale of controlling stake in Opella
Opella, headquartered in France, operates within the consumer healthcare sector in 100 countries
Johnson & Johnson submits application to the EMA for Darzalex SC-based quadruplet regimen for newly diagnosed multiple myeloma patients
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy
Roche says positive Phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members
PharmaJet and Scancell partner on needle-free DNA vaccine for melanoma
Under the agreement, Scancell will utilise the Stratis system for both clinical development and future commercialisation of its melanoma DNA vaccine
BeiGene’s Tevimbra gets Israeli approval for oesophageal squamous cell carcinoma
The approval makes Tevimbra available as a monotherapy for those suffering from the disease
Nura Bio closes Series A financing with $68m in new funds
Company announces successful completion of Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1 inhibitor